Cg Oncology, Inc. · NASDAQ:CGON

Cg Oncology — Technical Presentation (November 2025)

7 slides from Cg Oncology's technical presentation, November 2025

  1. Slide 1: CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study of Cretostimogene in High-Risk NMIBC

    CORE-008: A Phase-2, Multi-Arm, Multi-Cohort, Open-Label Study of Cretostimogene Grenadenorepvec for the Treatment of High-Risk NMIBC​​ Trinity J. Bivalacqua, MD, PhD, Siamak Daneshmand, MD, Neal D. Shore, MD, Shreyas S. Joshi, MD, and Colin P. Dinney, MD ​ 1 2 3 4 5 1 University of Pennsylvania, Ph

  2. Slide 2: CORE-008: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in High-Risk NMIBC

    CORE-008- A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle Invasive Bladder Cancer Trinity J. Bivalacqua, MD PhD; Siamak Daneshmand, MD; Neal D. Shore, MD; Shreyas S. Joshi, MD and Colin P. Dinney,

  3. Slide 3: Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action

    Oncolytic Immunotherapy: 2 Chain Reaction of Cancer Cell Death: Cretostimogene Grenadenorepvec’s Viral progeny spread to additional Dual Mechanism of Action tumor cells Selectively Replicates in and 1 Lyses Bladder Cancer Cells Enters target cell Replicates in and lyses cancer cells Innate to Adapti

  4. Slide 4: Phase 2, Multi-Cohort, Open-Label Study of Cretostimogene Grenadenorepvec in High-Risk NMIBC

    3 Phase 2, Multi-Cohort, Open-Label Study of Cretostimogene Grenadenorepvec in High-Risk NMIBC Cretostimogene Grenadenorepvec Primary Endpoint: High-Risk NMIBC CR (CIS) or HG-EFS Cohort A (BCG-naïve), Cohort B (BCG-exposed) (Papillary) Population / Key Entry Criteria Study Design / Regimen Additiona

  5. Slide 5: Pathological Inclusion Criteria

    Pathological Inclusion Criteria 4 NMIBC recurrence after BCG treatment Tre a t m e nt BCG induction only Adequate BCG Inadequate BCG o f re curre nce St a g e / Gra d e High grade High grade High grade CIS Any high-risk recurrence Ta/CIS T1 Ta/T1 ≤12 Mo 1st evaluation ≤6 Mo after Tim e t o e ve nt 3

  6. Slide 6: Treatment & Assessment Schedule

    5 Treatment & Assessment Schedule  Cystoscopy & Cytology every 3 months  Mandatory biopsy at week 51  CT/MRU every 6 months  Re-induction allowed for patients with HG Ta and/or CIS at Month 3  Treatment is optional in Year 3 Trinity Bivalacqua, MD, PhD

  7. Slide 7: Key Takeaways

    6 Key Takeaways • CORE-008 is a phase 2, multi-arm, multi-cohort trial evaluating cretostimogene in patients with HR NMIBC who are BCG-naïve or BCG- exposed • Cretostimogene is an oncolytic immunotherapy with dual MOA  Postulated innate to adaptive immune switching • Potentially effective, well tol

CG Oncology — Technical Presentation (November 2025) on 6ix